Episode 24 — 07 June 2026

NICE's revolutionary diabetes guideline makes SGLT-2 inhibitors first-line therapy while EU HTA regulation expands to high-risk medical devices. FDA accelerated approvals surge and EU clinical trial acceleration shows early progress toward 2030 targets.

Hosted by Marcus and Sara.

Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.

Full transcript and sources at outcomes-analytica.no/podcast